SK Bioscience Co Ltd (302440) — Capital Reinvestment Ratio

Latest as of September 2025: 3.44x

SK Bioscience Co Ltd (302440) has a Capital Reinvestment Ratio of 3.44x as of September 2025, meaning it reinvests 3% of its operating cash flow (₩20.65 Billion) in capital expenditures (₩70.94 Billion). Check tangible net worth ratio of SK Bioscience Co Ltd to evaluate the tangible quality of the company's equity base.

Capital Reinvestment Ratio

3.44x
Capex / Operating Cash Flow

Operating Cash Flow

₩20.65 Billion
KRW

Capital Expenditures

₩70.94 Billion
KRW

Data as of

Sep 2025
Most recent filing

SK Bioscience Co Ltd Capital Reinvestment Ratio (2018–2023)

This chart tracks SK Bioscience Co Ltd's Capital Reinvestment Ratio across 5 annual periods. For the full cash flow conversion analysis, see 302440 cash generation efficiency.

Annual Capital Reinvestment Ratio for SK Bioscience Co Ltd (2018–2023)

Year-by-year Capital Reinvestment Ratio for SK Bioscience Co Ltd from 2018 to 2023. See SK Bioscience Co Ltd free cash flow ratio to measure how efficiently the company converts operating cash flow to free cash.

Year Reinvestment Ratio Operating CF (KRW) Capital Expenditures YoY Change
2023 1.71x ₩29.35 Billion ₩50.30 Billion ▲ +2043.3%
2021 0.08x ₩536.59 Billion ₩42.91 Billion ▼ -3.2%
2020 0.08x ₩120.22 Billion ₩9.93 Billion ▼ -92.5%
2019 1.10x ₩21.82 Billion ₩23.97 Billion ▲ +159.4%
2018 0.42x ₩14.90 Billion ₩6.31 Billion
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow